Dr Sophie Postel-Vinay speaks to ecancer about the PIPSeN trial. Initially, she explains the background of this trial.
PIPSeN is a randomised, double-blind phase II study that evaluated the PARPi olaparib as maintenance treatment in patients with platinum-sensitive advanced NSCLC.
Dr Postel-Vinay then discusses the methodology and key results of this trial. PIPSeN was terminated early with only 50% of the pre-planned patient population available for analysis, thus being statistically underpowered.
She concludes that although well-tolerated, olaparib maintenance did not improve median PFS nor median OS in this sample of patients with platinum-sensitive NSCLC.
ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.